Humira®
Adalimumab is a fully human anti-TNF-α monoclonal antibody and the world's first fully human monoclonal antibody. It is one of the best-selling drugs in history.
| Dosage Form | SC Injectable (Prefilled Syringe / Pen) |
| Strength | 10 mg, 20 mg, 40 mg, 80 mg |
| Storage | Store at 2–8°C. Do not freeze. Protect from light. |
| Category | Immunology |
| Availability | Available for Transfer |
Rheumatoid arthritis; psoriatic arthritis; ankylosing spondylitis; Crohn's disease; ulcerative colitis; plaque psoriasis; juvenile idiopathic arthritis; uveitis; hidradenitis suppurativa.
Fully human IgG1 monoclonal antibody that binds specifically to TNF-α, blocking its interaction with p55 and p75 TNF receptors, reducing inflammatory signaling.
Each Burrard Pharmaceuticals technology transfer package for Adalimumab includes comprehensive documentation and support:
Complete formulation with manufacturing parameters, excipient specifications, and process controls.
Validated methods for assay, impurities, dissolution, and stability-indicating analysis.
Market-ready regulatory dossier templates — available through Burrard Intelligence subscription.
ICH-compliant stability studies (accelerated and long-term) with detailed protocols.
Scale-up procedures, batch records, equipment specifications, and in-process controls.
Direct advisory access to formulation scientists and regulatory specialists throughout transfer.
Our team can deliver the complete know-how package within 2–21 business days. Book a consultation to discuss your specific requirements.